ArticleInternational journal of molecular sciences2017
Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis.Clinical rheumatology · 2019Pooled it
- MMP-13, VEGF, and Disease Activity in a Cohort of Rheumatoid Arthritis Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy.Biology · 2021Review
- Potential clinical biomarkers in rheumatoid arthritis with an omic approach.Auto- immunity highlights · 2021Review
- Immune disorders and rheumatologic manifestations of viral hepatitis.World journal of gastroenterology · 2021Review
- The Role of Clinical and Ultrasound Enthesitis Scores in Ankylosing Spondylitis.Life (Basel, Switzerland) · 2021Article
- JAK/STAT pathway in pathology of rheumatoid arthritis (Review).Experimental and therapeutic medicine · 2020Review
- New insights into IL-17/IL-23 signaling in ankylosing spondylitis (Review).Experimental and therapeutic medicine · 2020Review
- Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.Clinical cardiology · 2020Review
- Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we aimed to estimate the concentrations of cytokines (interleukin 6, IL-6, tumor necrosis factor-α, TNF-α) and auto-antibodies (rheumatoid factor IgM isotype, IgM-RF, antinuclear auto-antibodies, ANA, anti-cyclic citrullinated peptide antibodies IgG isotype, IgG anti-CCP3.1, anti-cardiolipin IgG isotype, IgG anti-aCL) in serum of patients with eRA (early rheumatoid arthritis) and HCVrA (hepatitis C virus-related arthropathy) and to assess the utility of IL-6, TNF-α together with IgG anti-CCP and IgM-RF in distinguishing between patients with true eRA and HCVrA, in the idea of using them as differential immunomarkers. Serum samples were collected from 54 patients (30 diagnosed with eRA-subgroup 1 and 24 with HCVrA-subgroup 2) and from 28 healthy control persons. For the evaluation of serum concentrations of studied cytokines and auto-antibodies, we used immunoenzimatique techniques. The serum concentrations of both proinflammatory cytokines were statistically significantly higher in patients of subgroup 1 and subgroup 2, compared to the control group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.